Frequency of cytochrome P4502C9 allelic variants in the Chinese and French populations

被引:71
作者
Yang, JQ
Morin, S
Verstuyft, C
Fan, LA
Zhang, Y
Di Xu, C
Barbu, V
Jaillon, P
Becquemont, L [1 ]
机构
[1] Univ Paris 06, Assistance Publ Hop Paris, St Antoine Univ Hosp, Dept Pharmacol, Paris, France
[2] Shanghai Med Univ 2, Shanghai Inst Immunol, Dept Immunol, Shanghai, Peoples R China
[3] Shanghai Med Univ 2, Dept Pharmacol, Shanghai, Peoples R China
[4] St Antoine Hosp, Dept Mol Biol, F-75012 Paris, France
[5] St Antoine Hosp, Clin Invest Ctr, F-75012 Paris, France
关键词
CYP2C9; China; France; pharmacogenetics; polymorphism; single nucleotide; TaqMan polymerase chain reaction;
D O I
10.1046/j.1472-8206.2003.00148.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2C9 (CYP2C9) is a polymorphic enzyme responsible for the metabolism of different drugs with low therapeutic index such as oral anticoagulants. CYP2C9*2 and CYP2C9*3 are two single nucleotide polymorphic allelic variants. The frequency of these alleles in different ethnic populations is extremely variable. In this study, we compared the frequencies of CYP2C9 allelic variants among 394 Chinese living in Shanghai to 15 1 French Caucasians living in Paris. The allelic frequencies of CYP2C9 variants of the Chinese and the French subjects were 0.963, 0.001, 0.036 and 0.77, 0.15, 0.08 for CYP2C9*1, CYP2C9*2, CYP2C9*3, respectively. Chinese CYP2C9*3 allelic frequency was twice as lower as the French subjects, but three times higher than Korean (0.036 vs. 0.011). The CYP2C9*2 allele could be detected in only one Chinese subject, whereas it represented the major allelic variant in French Caucasians. The low frequency of the CYP2C9*2 and CYP2C9*3 allelic variants in Chinese subjects does not justify their detection in clinical practice, unlike French Caucasians.
引用
收藏
页码:373 / 376
页数:4
相关论文
共 15 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population [J].
García-Martín, E ;
Martínez, C ;
Ladero, JM ;
Gamito, FJG ;
Agúndez, JAG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :47-49
[3]   Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin [J].
Kidd, RS ;
Curry, TB ;
Gallagher, S ;
Edeki, T ;
Blaisdell, J ;
Goldstein, JA .
PHARMACOGENETICS, 2001, 11 (09) :803-808
[4]   Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele [J].
Kidd, RS ;
Straughn, AB ;
Meyer, MC ;
Blaisdell, J ;
Goldstein, JA ;
Dalton, JT .
PHARMACOGENETICS, 1999, 9 (01) :71-80
[5]   Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population [J].
Kimura, M ;
Ieiri, I ;
Mamiya, K ;
Urae, F ;
Higuchi, S .
THERAPEUTIC DRUG MONITORING, 1998, 20 (03) :243-247
[6]   Allelic discrimination using fluorogenic probes and the 5′ nuclease assay [J].
Livak, KJ .
GENETIC ANALYSIS-BIOMOLECULAR ENGINEERING, 1999, 14 (5-6) :143-149
[7]   Is diclofenac a valuable CYP2C9 probe in humans? [J].
Morin, S ;
Loriot, MA ;
Poirier, JM ;
Tenneze, L ;
Beaune, PH ;
Funck-Brentano, C ;
Jaillon, P ;
Becquemont, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 56 (11) :793-797
[8]   Genetic analysis of CYP2C9 polymorphism in a Japanese population [J].
Nasu, K ;
Kubota, T ;
Ishizaki, T .
PHARMACOGENETICS, 1997, 7 (05) :405-409
[9]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
[10]   Genetic analysis of the human cytochrome P450 CYP2C9 locus [J].
Stubbins, MJ ;
Harries, LW ;
Smith, G ;
Tarbit, MH ;
Wolf, CR .
PHARMACOGENETICS, 1996, 6 (05) :429-439